Clinical Report: Sleep Apnea’s Billion-Dollar Toll

Overview

Untreated obstructive sleep apnea (OSA) is linked to significant productivity losses, estimated at $180.2 billion in the US and £4.22 billion in the UK annually. The prevalence of OSA syndrome is notably high among working-age adults, yet diagnosis and treatment rates remain low.

Background

Obstructive sleep apnea (OSA) is a common condition characterized by repeated upper airway obstruction during sleep, leading to serious health and economic consequences. The condition not only affects individual health but also has substantial implications for workplace productivity. Despite its prevalence, many individuals remain undiagnosed or untreated, highlighting the need for improved screening and management strategies.

Data Highlights

Key Findings

• Estimated annual productivity loss per affected worker is $3727.40 in the US and approximately £1840 in the UK.
• Nearly 30% of US adults aged 18 to 64 years meet the criteria for OSA syndrome.
• 7% of UK adults aged 18 to 64 years meet the criteria for OSA syndrome.
• Diagnosis of OSA was based on self-reported symptoms rather than objective testing, which may lead to misclassification.
• Adherence to continuous positive airway pressure (CPAP) therapy is often suboptimal among patients.
• The economic burden of OSA may be underestimated as the analysis did not include additional healthcare costs or accident-related expenses.

Clinical Implications

Healthcare professionals should prioritize screening for obstructive sleep apnea in working-age adults, especially those exhibiting symptoms. Enhanced awareness and adherence to CPAP therapy are crucial for mitigating the economic and health impacts associated with untreated OSA.

Conclusion

The findings underscore the significant economic burden of untreated obstructive sleep apnea, emphasizing the need for improved diagnosis and management strategies to enhance patient outcomes and workplace productivity.

References

1. Neglected burden of obstructive sleep apnoea: workplace productivity loss in the USA and UK, UCL Discovery, 2023 -- Sleep Apnea’s Billion-Dollar Toll
2. ADA News — January JADA outlines emerging dental therapies for obstructive sleep apnea
3. BMC Psychiatry (Springer) — Investigating the role of depression in obstructive sleep apnea and predicting risk factors for OSA in depressed patients: machine learning-assisted evidence from NHANES
4. mayo clinic — Surgical treatment for obstructive sleep apnea
5. Contact Lens Spectrum — Dry Eye Dx and Tx
6. ADA News — January JADA outlines emerging dental therapies for obstructive sleep apnea
7. BMC Psychiatry — Investigating the role of depression in obstructive sleep apnea
8. Mayo Clinic — Surgical treatment for obstructive sleep apnea
9. VA/DOD Clinical Practice Guidelines for OSA
10. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity - PMC
11. Neglected burden of obstructive sleep apnoea: workplace productivity loss in the USA and UK - UCL Discovery